

Date: June 23, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Dear Sir/Madam,

Subject: Clarification on Discrepancies with regard to Outcome of Board Meeting-Financial Results for Quarter and year ended March 31, 2026

This is with reference to your email dated June 17, 2026 pertaining to certain discrepancies in Financial Results for the Quarter and Year ended March 31, 2026 submitted to the exchange on May 19, 2026. We would like to provide the following clarifications:

1. Mismatch in Yearly PAT Figures

Kindly note that the Profit After Tax (PAT) for the Financial Year 2025-26 reported in the PDF version of the financial statement for financial year ended March 31, 2026 is INR 5,917.92 million. The same amount of INR 5,917.92 million has been reported in the XBRL filing, thereby stating no mismatch in the PAT figures.

2. Non-disclosure of Consolidated EPS in XBRL

The non-disclosure of Consolidated Earnings Per Share (EPS) in the XBRL filing was due to an inadvertent clerical error during the filing process. The omission was unintentional and does not affect any other financial information disclosed by the Company.

The Company shall submit a revised XBRL filing with the Stock Exchange to incorporate the Consolidated Earnings Per Share (EPS) immediately after submission of this clarification letter.

We trust the above clarifications adequately address your observations and should any further information, clarification, or documents be required, we shall be pleased to provide the same.

We request you to kindly take the above clarifications on record.

Thanking you,

Yours truly,

For Anthem Biosciences Limited

(Formerly known as Anthem Biosciences Private Limited)

Divya Prasad

Company Secretary & Compliance Officer

Membership No: A41438